A CB2 Receptor Agonist Reduces the Production of Inflammatory Mediators and Improves Locomotor Activity in Experimental Autoimmune Encephalomyelitis | Zendy

Karim Parastouei | Zendy; Mohammad Hossein Aarabi | Zendy; Gholam Ali Hamidi | Zendy; Zahra Nasehi | Zendy; Shima Kabiri Arani | Zendy; Faezeh Jozi | Zendy; Mohamad Esmaeil Shahabodin | Zendy

Open Access

A CB2 Receptor Agonist Reduces the Production of Inflammatory Mediators and Improves Locomotor Activity in Experimental Autoimmune Encephalomyelitis

Author(s) -

Karim Parastouei,

Mohammad Hossein Aarabi,

Gholam Ali Hamidi,

Zahra Nasehi,

Shima Kabiri Arani,

Faezeh Jozi,

Mohamad Esmaeil Shahabodin

Publication year - 2022

Publication title -

reports of biochemistry and molecular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.467

H-Index - 8

ISSN - 2322-3480

DOI - 10.52547/rbmb.11.1.1

Subject(s) - experimental autoimmune encephalomyelitis , agonist , medicine , receptor , neuroscience , immunology , pharmacology , multiple sclerosis , biology

Cannabinoids (CBs) have been found to regulate the immune system, affect innate and adaptive immune responses, and reduce inflammatory reactions. This study assessed the therapeutic effects of GW-405833 synthetic CB2 agonist on inflammatory factors as well as locomotor activity in experimental autoimmune encephalomyelitis (EAE).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research